Tarsus Pharmaceuticals reported a significant net loss of $693.9 million for the nine months ended September 30, 2026, primarily driven by $632.2 million in acquired in-process research and development expenses from the acquisitions of iRenix and Alkeus. Despite the net loss, total revenues grew to $530.5 million, up from $299.7 million in the prior year, fueled by strong product sales.
Tarsus Pharmaceuticals reported record third quarter 2026 financial results, highlighted by XDEMVY net product sales of $194.6 million, a 64% year-over-year increase. The company surpassed one million bottles dispensed and $1 billion in cumulative net sales since the product's launch, while also announcing the appointment of Neera Clase as Chief Commercial Officer.
“XDEMVY has shown what that focus can achieve. In just three years since launch, we have dispensed more than one million bottles and generated $1 billion in cumulative net product sales, and with continued robust growth, we are only getting started. That strength is helping us build one of the most differentiated pipelines in eye care, with the potential to bring five medicines to patients in the next five years.”
Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus
Tarsus Pharmaceuticals M&A Deal with Alkeus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals filed an amendment to its previous 8-K to provide required historical and pro forma financial statements following its acquisition of Alkeus Pharmaceuticals. The acquisition was originally completed on September 4, 2026, pursuant to a merger agreement dated July 31, 2026.